Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope

Yuval Avnir
Harvard Medical School

Kristina L. Prachanronarong
University of Massachusetts Medical School

Shurong Hou
University of Massachusetts Medical School

See next page for additional authors

Follow this and additional works at: https://escholarship.umassmed.edu/schiffer

Part of the Biochemistry Commons, Medicinal Chemistry and Pharmaceutics Commons, Medicinal-Pharmaceutical Chemistry Commons, Molecular Biology Commons, Structural Biology Commons, and the Therapeutics Commons

Repository Citation
https://escholarship.umassmed.edu/schiffer/17

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Schiffer Lab Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope

Authors
Yuval Avnir, Kristina L. Prachanronarong, Shurong Hou, Brendan J. Hilbert, Markus-Frederik Bohn, Timothy F. Kowalik, Robert W. Finberg, Jennifer P. Wang, Nese Kurt Yilmaz, Celia A. Schiffer, and Wayne A. Marasco

Keywords
IGHV polymorphism, VH germline genes, anti-idiotypic antibody, anti-influenza antibodies, chronic lymphocytic leukemia, cross-reactive idiotype, crystal structure, immunoglobulin germline genes, influenza

Comments
Full author list omitted for brevity. For the full list of authors, see article.

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Rights and Permissions
Copyright 2017 The Authors. Open Access funded by the US Department of Defense (DoD) or performed by an employee of DoD. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

This article is available at eScholarship@UMMS: https://escholarship.umassmed.edu/schiffer/17
Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope

Highlights
- G6 binds to a subset of IGHV1-69 germline-based anti-influenza Abs
- The structure of humanized G6 with a IGHV1-69 anti-influenza Ab is reported
- Various binding assays further define the G6 cross-reactive binding idiotope
- The core binding idiotope of G6 is deduced

In Brief
G6 is an exceptional anti-idiotypic antibody that binds to antibodies encoded by the immunoglobulin heavy chain germline gene IGHV1-69. Avnir et al. describe how G6 binds to its cross-reactive idiotope by a set of binding assays and by solving the structure of humanized-G6 complexed with an IGHV1-69-anti-influenza Ab.

Authors
Yuval Avnir, Kristina L. Prachanronarong, Zhen Zhang, ..., Nese Kurt Yilmaz, Celia A. Schiffer, Wayne A. Marasco

Correspondence
nese.kurtyilmaz@umassmed.edu (N.K.Y.), celia.schiffer@umassmed.edu (C.A.S.), wayne_marasco@dfci.harvard.edu (W.A.M.)

Data and Software Availability
5JQD
5JO4
Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotype

Yuval Avnir,1,2,3 Kristina L. Prachanronarong,3,9 Zhen Zhang,1,2,3 Shurong Hou,3 Eric C. Peterson,1,2 Jianhua Sui,1,2 Hatem Zayed,1,2 Vinodh B. Kurella,1,2,3 Andrew T. McGuire,3 Leonidas Stamatakis,6 Brendan J. Hilbert,3 Markus-Frederik Bohn,1 Timothy F. Kowalik,3 Jeffrey D. Jensen,7 Robert W. Finberg,5 Jennifer P. Wang,5 Margaret Goodall,8 Roy Jefferis,8 Quan Zhu,1,2 Nese Kurt Yilmaz,3,* Celia A. Schiffer,3,* and Wayne A. Marasco1,2,10,*
1Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA
2Department of Medicine, Harvard Medical School, Boston, MA, USA
3Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
4Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
5Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
6Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA, USA
7School of Life Sciences, Center for Evolution and Medicine, Arizona State University, Tempe, AZ, USA
8Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
9These authors contributed equally
10Lead Contact
*Correspondence: nese.kurtyilmaz@umassmed.edu (N.K.Y.), celia.schiffer@umassmed.edu (C.A.S.), wayne_marasco@dfci.harvard.edu (W.A.M.)
https://doi.org/10.1016/j.celrep.2017.11.056

SUMMARY

The heavy chain IGHV1-69 germline gene exhibits a high level of polymorphism and shows biased usage in protective antibody (Ab) responses to infections and vaccines. It is also highly expressed in several B cell malignancies and autoimmune diseases. G6 is an anti-idiotypic monoclonal Ab that selectively binds to IGHV1-69 heavy chain germline gene 51p1 alleles that have been implicated in these Ab responses and disease processes. Here, we determine the co-crystal structure of humanized G6 (hG6.3) in complex with anti-influenza hemagglutinin stem-directed broadly neutralizing Ab D80. The core of the hG6.3 idiotope is a continuous string of CDR-H2 residues starting with M53 and ending with N58. G6 binding studies demonstrate the remarkable breadth of binding to 51p1 IGHV1-69 Abs with diverse CDR-H3, light chain, and antigen binding specificities. These studies detail the broad expression of the G6 cross-reactive idiotype (CRI) that further defines its potential role in precision medicine.

INTRODUCTION

With the emerging field of precision medicine comes an expanding need to understand immunoglobulin (Ig)-biased gene utilization at the molecular level so that vaccines with universal efficiency in the population can be deployed. In the fields of cancer and autoimmune disease, targeted immunotherapies require knowledge of antibody (Ab)-protein interactions at the molecular level. Human immunoglobulin heavy-chain (IGHV) polymorphisms are recognized as a rich source of humoral immune system diversity, and the structural importance of the heavy chain (VH) in binding interactions is well-established (Watson et al., 2017). Structural and copy-number variations in many IGHV loci can lead to wide variability in expression levels and biological activity of Abs and B cell receptors (BCRs) (Avnir et al., 2016; Watson and Breiden, 2012; Watson et al., 2013).

Anti-idiotypic (anti-Id+) antibodies are defined as those capable of binding to the variable domains of other Abs (idiotypes) (Grey et al., 1965; Kunke1 et al., 1963; Oudin and Michel, 1969a, 1969b). In 1986, Mageed et al. (1986) generated mouse anti-Id+ G6 by immunization with a human rheumatoid factor (RF) Ab of the Wa group. G6 was shown to bind to the RF heavy chain, not to the light chain. Through sequencing VH genes of G6-reactive RFs (Newkirk et al., 1987) and G6-reactive CLL B cells (Kipps et al., 1989), it became apparent that the G6 binding idiotope is encoded by the 51p1 allele family of IGHV1-69 germ-line genes (Kipps et al., 1989; Schroeder et al., 1987) that are defined by CDR-H2 Phe54 (F-alleles) as opposed to the G6 nonreactive hv1263 germline gene alleles that encode CDR-H2 Leu54 (L-alleles) (Potter et al., 1999). Currently, the International Immunogenetics Information System (IMGT) database lists 14 IGHV1-69 alleles, eight belong to the F-allele group and six to the L-allele group that show remarkably variable distribution across different ethnic populations (Avnir et al., 2016).

The expression of the G6 cross-reactive idiotype (CRI) is well-studied (Charles et al., 2013; Potter et al., 1999). Sasso et al. (1996) first reported that IGHV1-69 gene copy number correlates with the frequency of tonsillar B cells positively stained with G6; presence of G6-reactive cells in the mantle zones of secondary B cell follicles may be strategic for host defense (Cerutti et al., 2013). In B cell chronic lymphocytic leukemia (B-CLL)
The unique anti-Id\(^*\) properties of G6 and its potential use in the monitoring and treatment of IGHV1-69 Ab responses and associated diseases, respectively, motivated us to comprehensively study the G6 idiotope at the atomic level. In the present study, the co-crystal structures of a potent humanized G6, hG6.3 (Chang et al., 2016), bound to HV1-69-sBnAb D80 (Sui et al., 2009), and D80 alone are reported to 2.5 Å resolution. Detailed comparative structural analysis permitted the determination of the hG6.3 idiotope. Additional binding and modeling studies of a large panel of G6-reactive Abs as well as HV1-69-sBnAbs and their variants were performed. The G6 CRI is expressed on IGHV1-69 Abs with widely varying CDR-H3, light chains, and antigen specificities. Remarkably, the G6 CRI is lost on the majority of HV1-69-sBnAbs due to critical mutations around the idiotope core at CDR-H2 Phe54 that are requisite for HA binding. These hG6.3 studies provide a precise delineation of the G6 CRI and a rationale for using hG6.3 to monitor IGHV1-69 Ab responses to vaccination and infection and advance anti-Id\(^*\)-based immunotherapies.

RESULTS

Defining the G6 Idiotype on IGHV1-69-Encoded Human Anti-influenza Abs Targeting the HA Stem Domain

We (Sui et al., 2009) and others (Corti et al., 2017; Pappas et al., 2014) discovered the biased use of IGHV1-69 F-alleles in HV1-69-sBnAbs. These data led us to further investigate if these HV1-69-sBnAbs also bind to the anti-Id\(^*\) Ab G6. Surprisingly, an ELISA assay showed that of the five previously discovered HV1-69-sBnAbs (Sui et al., 2009), only D8 strongly bound to G6 (Figure 1A). Very weak binding was also observed for the IGHV1-2 germline-based sBnAb H40. In subsequent assays that tested G6 binding of 7 other HV1-69-sBnAbs, only CR6331 (Throsby et al., 2008) and 70-1F02 (Wrammert et al., 2011) were found to express the G6 CRI. In addition, no binding activity was observed when C9114 (Oreyfus et al., 2012) was tested for binding against humanized hG6.3 (Chang et al., 2016). Thus, of a total of 12 HV1-69-sBnAbs that were tested, only three were G6-reactive. Analysis of the three G6-reactive heavy chain CDR sequences (Figure 1B) revealed the commonality of P52aA/G substitution in CDR-H2 together with shorter CDR-H3 regions that encode three tyrosine residues at positions 97–99 (Kabat numbering). The G6-reactive HV1-69-sBnAbs maintained germline N58. Fewer amino acid substitutions occur in CDR-H1 and CDR-H2, with higher V-segment germline gene identity (92.0% ± 3.5%), for G6-reactive compared to the G6-nonreactive HV1-69-sBnAbs (85.1% ± 1.5%).

Three of these G6-nonreactive HV1-69-sBnAbs, F10, A66, and CR6261, were used to investigate the contributions of V-segment amino acid substitutions, whereby the expression of G6 idiotope was analyzed for chimeras constructed by using the IGHV1-69 germline non-mutated V-segment and maintaining the original (wild-type; WT) CDR-H3/J and light chains. Restoration of strong G6 binding was observed for the three VH1-69/F10, VH1-69/A66, and VH1-69/CR6261 chimeras (Figure 2A) that now failed to bind HA (data not shown). This finding of reciprocal gain of G6-idiotype with loss of HA binding was unexpected. We have previously shown that a consensus motif for HV1-69-sBnAbs is composed of critical amino acid substitutions in the VH1-segment together with a hydrophobic amino acid at position 53, Phe54, and properly positioned...
CDR-H3 Tyr (Avnir et al., 2014). Thus, unique VH-segment substitutions, particularly those involving the CDR-H2 loop, are involved in HA binding.

To further define the contribution of individual VH-segment substitutions for G6 and HA binding, several VH1-69/F10 variants were tested in which amino acid substitutions were back-introduced into CDR-H2 (Figures 2B and 2E). The substitutions of either I52S or I53M resulted in lower G6 binding affinity, as determined by faster dissociation rates, and the combined I52S I53M substitutions resulted in a significant loss in binding affinity. Interestingly, in contrast to our previous report (Avnir et al., 2014) that showed that VH1-69/F10 CDR-H2 I52S restored binding activity to HA, while VH1-69/F10 CDR-H2 I53M did not, both constructs had a similar effect on diminishing G6 binding. In addition, the VH1-69/F10 CDR-H1 G26E G27V CDR-H2 I52S I53M variant (that introduced two HV1-69-sBnAb amino acid changes in CDR-H1) resulted in complete loss of G6 binding.

This set of VH1-69/F10 variants was also displayed using artificial BCRs and tested against G6 and hG6.3 as antigens. Both G6 and hG6.3 were able to cross-link the various VH1-69/F10 variants, but not the WT F10. In contrast to the kinetic binding data (Figure 2B), the VH1-69/F10 CDR-H2 I52S and VH1-69/F10 CDR-H2 I53M variants had similar and modest increases in binding, respectively, compared to VH1-69/F10, and the combination CDR-H2 and CDR-H1/H2 variants also maintained some level of G6 binding. This disparity may be attributed to avidity in the BCR experimental system that is generated by bivalent to bivalent interactions (Vauquelin and Charlton, 2013). Thus, the G6 idiotope is exclusively located in the VH segment and is most sensitive to amino acid changes.

Figure 2. Analysis of G6 Idiotype by Using HV1-69-sBnAb Variants
(A) The V-segment of the non-G6 reactive HV1-69-sBnAbs F10, CR6261, and A66 was replaced with the non-mutated IGHV1-69*01 germline V-segment. Binding kinetics of the three variants (VH1-69/F10, A66, CR6261) were analyzed against G6 by using Biacore T100.

(B) VH1-69/F10 variants were generated, in which F10’s V-segment amino acid substitutions were back-introduced and then analyzed by Biacore T100 for binding activities against G6 when using a single concentration of 2.85 µg/mL per variant.

(C and D) The same variants were also tested for binding by using an artificial B cell receptor display system in which the VH1-69/F10 variants were displayed as BCRs and either G6 (C) or hG6.3 (D) were added at the concentration of 50 µg/mL. In the upper panels of (C) and (D), the binding response is shown for isotype controls and varying concentrations of G6 or h6.3 when tested against VH1-69/F10. Binding was monitored by fluorescent measurements of calcium ions being released from intracellular compartments.

(E) The heavy chain of F10 is shown (PDB 3FKU) with residues colored in red that were back-introduced in the VH1-69/F10 variants and the unchanged CDR-H3/J residues are shown in pink.
in CDR-H2 but can be further influenced by amino acid changes in CDR-H1.

The Crystal Structures of the D80 Fab Fragment and the D80-hG6.3 Fab Fragment Complex

The G6 idiotope was further elucidated at the structural level by investigating the critical binding interactions of one of these HV1-69-sBnAbs, D80 (that has a similar VH chain as D8 except for a K23R substitution) that binds both HA and hG6.3. The crystal structures of the Fab of D80 were determined for both D80 alone and bound to the hG6.3 Fab, each to 2.5 Å resolution (Figure 3; Table S1). Macro level view of the hG6.3-D80 complex shows that the two Abs form an angle of ~130° with respect to the length and height of the centroid planes (Figure 3A). The binding interface between D80 and hG6.3 has a total buried solvent-accessible surface area of 900 Å² per binding partner. The two antibodies interact with each other through their variable domains, where the CDR loops in the VH domain of D80 Fab directly interact with their complementary CDR loops in the VH and light chain (VL) domains of the hG6.3 Fab (Figure 3B).

Intermolecular Binding Interface between D80 and hG6.3

To quantify the extent of interactions made by the CDRs, the intermolecular van der Waals (vdW) contact energies were calculated and mapped onto the structures of D80 and hG6.3 (see the Supplemental Experimental Procedures) (Figure 3B). Among the CDRs of D80, CDR-H2 contributes the most to the binding interface with the largest magnitude of total vdW contact energy (~7.5, ~30.9, and ~7.0 kcal/mol for CDR-H1, -H2, and -H3, respectively), confirming that the hG6.3 binding idiotope is primarily located on CDR-H2 (red residues in Figure 3B, lower right). The residues that make the most extensive contacts with hG6.3 are M53 and F54 in CDR-H2, and at the edge, N58. The N58 side chain makes 3 intermolecular hydrogen bonds that are part of a larger hydrogen bonding network that stabilizes the bound complex across the interface (Figure 4A). A substitution at this position to cause loss of these hydrogen bonds would destabilize and likely disrupt the binding interaction. In agreement with this observation, all 3 HV1-69-sBnAbs that are G6-reactive have the germline N58. In contrast, 8 of the 9 G6-unreactive Abs have a substitution at position 58, with 6 Abs containing an N58K substitution, CR9114 having
N58A and D7 an N58S substitution. None of these substitutions would be able to retain the intermolecular side chain hydrogen bonds. Only the G6-nonreactive F10 has germline N58, this exception is discussed below. Additionally, D80 CDR-H2 residues G55 and T56 and CDR-H3 residues Y98 and Y99 also significantly contribute to the packing between the two Abs (Figure 3C, right), followed by CDR-H1 residues T31 and S33 and the framework residue E73.

In hG6.3, most of the intermolecular vdW interactions are contributed by Y97 followed by W33 of the heavy chain and F94, Y91, Q93, N32, and S30 of the light chain (Figures 3B and 3C, left). D80’s M53 and F54 form a “knuckle” that inserts into a pocket with M53 and G55 extensively interacting with Y97 and W33 of the hG6.3 heavy chain and F94 packs against Y91 of the light chain. The pocket in hG6.3 where this “knuckle” inserts is not entirely filled by D80 and may play a role in the diversity of antibody binding to hG6.3. A volume of 32 Å³, as calculated by POVME (Durrant et al., 2014), lined by hydrophobic atoms remains (Figure S1), indicating the pocket could accommodate other hydrophobic side chains.

In addition to the vdW contacts, which capture the surface-surface packing and shape complementarity at the binding interface, additional contributions by polar (hydrogen bonding) and pi-stacking interactions were analyzed to define the full hG6.3 idiotope (Figure 5; Table S2). In CDR-H1, residues T31, S33, and Y35 have side chain hydrogen bonds with VH residues W33 and D56 of hG6.3 (Figure 5A). As with vdW contacts, CDR-H2 of D80 contributes the most to the interactions with hG6: the side chain of T52, T56, and N58 of D80 have hydrogen bonds to the VL residues N32, S92, and Q93 of hG6.3. The backbone carbon of G55 in this loop is also involved in a pi-stacking interaction with Y99 of hG6.3 (Figure 5B, inset). The only polar CDR-H3 interaction is pi-stacking between VH Y99 and hG6.3 VL F94 (Figures 5C and 5D). This Tyr is part of the triple Tyr motif (Y97–Y99) that participates in an extensive pi-stacking interaction network involving CDR-H2, CDR-H3, and hG6.3 residues.
F94 (VL) and W33 (VH) (Figure 5D). The VL of D80 also makes one hydrogen bond from R96 to hG6.3 Q90 (Table S2). Taken together, analysis of vdW, hydrogen bonding, and pi-stacking interactions identify D80 residues that contribute to intermolecular interactions with the G6 as CDR-H1 positions 31 and 33, CDR-H2 positions 53–58, and CDR-H3 positions 97–99, with the key positions of the idiotope located on CDR-H2.

Comparison of D80 Unbound and hG6.3-Bound Structures

The overall unbound versus hG6.3-bound D80 structures do not have any major backbone changes except a slight increase in the angle between the VH and CH1 domains relative to each other (1°/C14–3/C14, Figures S2A–S2C), which may also be affected by crystal packing, suggesting a lock-and-key type protein-protein binding. To compare the bound and unbound structures quantitatively, the distance difference matrix was calculated for the heavy chain of D80 Fab fragment (Figures S2D–S2F; Supplemental Experimental Procedures). In accordance with the increase in inter-domain angle, the majority of distance changes correspond to increase in distance between residues in D80’s VH and CH1 domains when bound to hG6.3. Within each domain the changes were much more subtle, with the most considerable changes in the CDR-H1 loop and a few residues displaying distance changes of more than 2 Å in CDR-H2 and CDR-H3 loops. The pi-stacking interaction network described above (Figure 5D) is conserved between the unbound and bound structures of D80 and may contribute to stabilizing the loop structures in a binding-competent state in the unbound form. Overall, the similarity of CDR loops regardless of whether D80 is bound to hG6.3 or not indicates that the epitope pre-exists in the unbound state and does not need to undergo major conformational changes for binding to occur. Hence, this similarity promises that the D80-hG6.3 crystal structure determined here can serve as an appropriate template to model the binding of other G6-reactive Abs for which unbound structures are available.

Substituting CDR-H2 F54 or N58 Has Differential Effects on hG6.3 and HA Binding

F54L substitution in an IGHV1-69 F-allele Ab has been shown (Potter et al., 1999) to completely abolished binding to G6. To test whether D80 F54 is critical for binding, an F54L variant was engineered and binding affinity was completely abolished (Figure 6A). Molecular modeling of F54L on the hG6.3-D80 crystal structure (Figures 6C and 6D) predicted a substantial loss of intermolecular vdW contacts. Specifically, F54 aromatic ring forms extensive vdW contacts with hG6.3 light chain Y91. The smaller L54 would not reach the Y91 CB atom and thus cannot form these interactions. This decrease in vdW contacts may also affect the stability of the extensive pi-stacking interaction network involving D80 CDR-H2 and CDR-H3 (Figure 5D). In addition, L54 substitution would result in decrease of vdW contacts with light chain P96 and heavy chain H35 and S95, amounting to a total predicted loss of 5 kcal/mol in vdW contact energy. Interestingly, while G6-binding is lost with the F54L substitution, equivalent binding is still maintained against H5VN04 HA (Figure 6B). The similar binding profile of D80 WT and D80 F54L to HA suggest that F54 in D80 does not have a critical role in HA binding and rather binding is mainly mediated through CDR-H3 Y98 (Avnir et al., 2014). This observation is also in agreement with the study by Pappas et al. (2014) that somatic mutations in the VH-segment of HV1-69-sBnAbs can compensate for the critical role of F54 in HA binding.

In addition, substitutions at position 58 are detrimental to G6 binding, however, all the HV1-69-sBnAbs defined by substitutions at position 58 (Figure 1) are still able to bind HA (except of F10, discussed below). In the available crystal structure of F10 bound to HA, the germine-encoded residue of N58 is located on a beta strand following CDR-H2 and does not make any hydrogen bonds or vdW contacts with HA (Sui et al., 2009). Aligning the D80 Fab structure onto F10, N58 is located...
in the same position in D80 with respect to HA and hence is not involved in any intermolecular interactions (Figure 4B). Thus, the difference in the epitope used by D80 in hG6.3 versus HA binding explains why HV1-69-sBnAbs with a substitution at N58 can retain HA binding despite becoming G6-unreactive.

Establishing Specificity of G6 Binding to IGHV1-69 F-Alleles through scFv-Phagemid Library Panning

The breadth of G6 reactivity for rearranged IGHV1-69 genes was further investigated. An assay was developed in which our 27 billion-member Mehta I/II non-immune human Ab scFv-phagemid-Ab library was panned against beads coupled with G6 (Figure 7). DNA sequences from the phagemid-Abs recovered from the beads confirmed that G6 is highly specific to IGHV1-69 F-allele group Abs (Figure 7A). Long-read PacBio next generation sequencing of the pre-selected phagemid-Ab library confirmed the G6-selected IGHV1-69 F-allele-encoded Abs was not due to the biased Mehta I/II library composition or due to absence of IGHV1-69 L-alleles (not shown). High diversity in the eluted Abs was observed with respect to D-segments (Figure 7B), J-segments (Figure 7C), and CDR-H3 length (Figure 7E). Promiscuous use of kappa and lambda light chains was also noted (Figure 7D).

A single noticeable difference in the D-segment usage between the G6-selected and unselected Abs is that the former had only one Ab comprised of the IGHD2-15’01 D-segment, which does not encode CDR-H3 Tyr’s in any reading frame, versus ~8% in the unselected Abs (Figure S3A).

V-segment analysis revealed preferential binding to non-mutated V-segments (Figures 7F and S4). Our analyses reveal a paucity of CDR-H2 amino acid substitutions (Figure 7G): explicitly, of the 142 IGHV1-69*01 Abs, only 13 Abs had amino acid substitutions in the CDR-H2 domain, while 36 Abs had amino acid substitutions in the CDR-H1 domain (Figure S4). This biased distribution of CDR-H1 versus CDR-H2 substitutions is in line with the importance of germline CDR-H2 residues mentioned above. In addition, none of the CDR-H2 substitutions involved changes in F54, while analysis of CDR-H2 amino acid sequences of 75 IGHV1-69 hv1263 allele-encoded Abs in the pre-selected library showed that 8 had L54F substitutions, and of these, none exhibited complete reversal to the F-allele 51p1 CDR-H2 sequence IIPIFGTA, thereby further demonstrating the unlikelihood of G6 binding to hv1263 allele-encoded Abs (Figure S3B).

G6 and hG6.3 Favor Binding to Antibodies Defined by Non-mutated IGHV1-69 V-Segments

A subset of G6-reactive phagemid-Abs from the panning assays with a range of V-segment mutations was chosen and analyzed for their binding against both G6 and hG6.3 by ELISA assay that utilized the Meso Scale Discovery (MSD) technology. The MSD
signal obtained from four dilution points was used to calculate area under the curve (AUC) values and these were tabulated in Figure S5A. The majority of the IGHV1-69 phagemid-Abs (17 of 19) were defined by AUC values that were within or above one SD of the mean (mean ± 1 SD = 6.89E + 05 ± 3.55E + 05; hG6.3 = 6.80E + 05 ± 2.83E + 05). However, two Abs (S60 and F66) encoding a germline CDR-H2 region had lower AUC values than the mean minus one SD. Although, they did have 8 and 2 substitutions, respectively, in their V-segments inspection of these two Abs against the panel of Abs that showed stronger hG6.3 binding did not reveal an obvious cause for the weaker binding (Figure S5B). In agreement with our previous report on humanization of G6 (Chang et al., 2016), D80 had weaker binding activity against G6 and hG6.3 as defined by the AUC values of 1.67E + 05 and 7.83E + 04, respectively, and the three non-IGHV1-69 phagemid-Abs exhibited only background binding activities that were defined by an average AUC of G6, mean ± 1 SD = 3.68E + 03 ± 2.50 + 03; hG6.3, 2.69E + 03 ± 2.12E + 03. From these studies, we conclude that G6 shows preferential binding for the germline CDR-H2 loop, and with a few exceptions, does not show major differences between the IGKV1-69 F-allele Abs despite variability in V-segment amino acid substitutions, CDR-H3 composition, and type of light chain.

The Binding Conformation of IGKV1-69 Abs with Non-mutated V-Segment against hG6.3 Based on the D80 Crystal Structure

The D80-hG6.3 structure was then used to model the binding of IGKV1-69 Abs comprised of non-mutated V-segments. Two 51p1 IGKV1-69 Abs with germline V-segments and available unbound crystal structures, 1-69/B3 (Teplyakov et al., 2016), and 3B4 (Tu et al., 2016), were expressed as scFv-phagemid Abs
and were found to bind G6/hG6.3 stronger than D80 in MSD ELISA assay (data not shown). The unbound structures were aligned onto the D80 in the complex, followed by energy minimization (see the Experimental Procedures). The CDR-H2 in the resulting G6-bound structures of both Abs superimpose very well with D80 (Figure S6). Most importantly, 1-69/B3 and 3B4 are able to maintain the critical interactions of F54 and N58 in CDR-H2 (Figures S6C and S6D). However, 3B4 and 1-69 have more extensive contacts with hG6.3 compared to D80, resulting in more buried solvent accessible surface area upon binding (1,400 Å²; more than 50% compared to D80) and a corresponding more than 50% increase in the intermolecular vdW interaction energy. This increase is due to enhanced intermolecular interactions of CDR-H3 as well as with VL, suggesting that while the conformation of CDR-H2 is critical to G6 binding, further interactions including those with CDR-H3 and the light chain can enhance the binding strength of G6-reactive Abs.  

**HV1-69-sBnAb F10 Is G6-Unreactive Due to Prolines in CDR-H2**

Finally, to understand why HV1-69-sBnAb F10 is G6-unreactive despite retaining the germline N58, binding of F10 to hG6.3 was modeled using the D80-hG6.3 crystal structure as a template (Figure 4C). When F10’s CDR-H2 is aligned onto the D80 structure to maintain the critical van der Waals contacts of the F54 side chain, N58 is positioned too far away from hG6.3 to maintain any of its three intermolecular hydrogen bonds (Figure 4; Table S2). This displacement relative to the same position in D80 is due to a kink in the beta strand following CDR-H2 caused by a proline substitution at position 57 preceding N58. Thus, the proline substitution at position 57 rigidifies CDR-H2 and creates a kink in the backbone structure that renders F10 unable to simultaneously establish the key F54 and N58 interactions. In accordance, none of the HV1-69-sBnAb with an A57P substitution in our initial panel was G6 reactive (Figure 1B). However, mutation of position 57 back to Ala in F10 was not sufficient to restore G6 reactivity (data not shown), most likely due to an I53M substitution next to a second proline in CDR-H2, the germline P52a. The M53 side chain has a different conformation in F10 compared to D80 and can be accommodated at the binding interface only in the presence of a neighboring P52aG substitution that allows backbone flexibility, as is the case in D80. Thus, G6 binding can be lost in multiple ways, including due to a substitution of the critical germline N58 itself, or a proline substitution at the preceding A57 that causes N58 to lose intermolecular interactions.

**DISCUSSION**

The anti-Id+ IGHV1-69 Ab G6 has been used extensively for over 30 years to characterize biologically important antibody processes in humans. Since G6’s discovery, recognition of important functions of IGHV polymorphism and related biased germline gene usage in wellness and disease has grown, yet there is a paucity of well-characterized anti-Id+ reagents that can be used to monitor these serologic responses. In this study, an in-depth investigation was conducted into the binding epitope of the humanized version of G6, hG6.3 (Chang et al., 2016). We solved the crystal structures of hG6.3 in complex with anti-influenza HV1-69-sBnAb D80, and D80 alone (Figure 3). The hG6.3 idiotope is centered around the CDR-H2 loop of D80, with the M53 and F54 at the tip of this loop inserting into a pocket in hG6.3, and the core of the idiotope extending to N58 (Figures 4 and 5) and interacting with both the heavy and light chains of hG6.3 (Figure S7). G6 prefers binding to Abs for which CDR-H2 is in the germline configuration (Figures 7, S4, and S5). The anti-Id tolerates hydrophobic amino acid substitutions at position I53 (Figure S4); however, in striking contrast, the critical role of germline F54 for binding is absolute. The germline CDR-H2 boundary residue N58 (Figure 4), which participates in an intermolecular hydrogen bonding network, also greatly contributes to the binding energy. Maintaining the interactions of both F54 and N58 simultaneously is required for binding G6 but not for HA binding where only the former is necessary. The G6 idiotope also appears to require germline G55 as other side chains would sterically clash with Tyr91 (Figures 1B, S4, and S7B); however, this position is not invariant for HV1-69-sBnAbs (Avnir et al., 2014). Small amino acid side chain substitutions of T56V, T56A, and T56S are rarely found but larger side chains are not seen and would be predicted to clash with hG6.3 light chain residues (Figures S4 and S7). We conclude that the hG6.3 angle of approach to the main core of the idiotope, which is a continuous string of CDR-H2 residues starting with M53 and ending with N58 is such that hG6.3 provides a hydrophobic pocket lined between the heavy and light chains where M53 and F54 side chains are inserted, whereas the hG6.3 light chain provides polar side chains (N32, S92, Q93) that form hydrogen bonds to T56 and N58.

The binding interaction observed between hG6.3 and D80, in which the D80 idiotope is not centered on the axis of the β-barrel formed by the β strands of the VH and VL domains, is unusual but not unprecedented. Co-crystallographic studies of human IgM RF-AN bound to IgG4 Fc showed that the Abs involved in autorecognition are all located at the edge of the conventional combining site surface, leaving much of the RF light chain CDRs (CDR-L1, -L2, and -L3) potentially available for recognition of a different antigen (Corper et al., 1997). hG6.3 binding to D80 results in the hG6.3 heavy chain covering the apex of the D80 heavy chain and the hG6.3 light chain is positioned in front of the D80 heavy chain-light chain interface. This topography of interaction results in the notable lack of any contribution from D80 CDR-L1 and -L2 to hG6.3 binding (Figure 3C). Whether this remaining D80 VL surface area could be available for binding another antigen is unknown but would require a narrow angle of approach that does not rely on the main CDR loops of D80. Because D80 utilizes the IGKV3-20 light chain germline gene, this could be tested experimentally with anti-IGKV3-20 idiotypic Abs or antigens that show biased binding of this light chain (de Re et al., 2009). A similar hypothesis could be made for any of the Id+ IGHV1-69 Abs that are recognized by G6.

The results from the G6 panning studies (Figure 7) demonstrate the remarkable breadth of binding to the family of 51p1 IGHV1-69 Abs. The hG6.3:D80 co-crystal structure shows that the pocket in hG6.3 is not entirely filled by D80, but could play a role in the diversity of antibody binding (Figure S1). A wide variety of CDR-H3 compositions with varying length and amino acid substitutions are tolerated (Figures 7 and S4). The crystal
structure demonstrates that hG6.3 primarily makes contact with the D80 heavy chain, which is in agreement with the broad range of light chain pairing that is seen from our G6 panning studies. Soluble VH1-69/F10 VH domains also bind G6 with even higher affinity than VH1-69/F10 scFvs that may be due to an increase in buried surface area and contacts with CDR-H3 (Figure 3B and data not shown). Many CDR-H1 substitutions appear to be well-tolerated, as are substitutions in FR1-3 and CDR-H4 (Avnir et al., 2014; Selâ-Culang et al., 2013) in contrast to the paucity of CDR-H2 amino acid substitutions that forms the core of the G6 idiotope (Figure S4). In agreement with the lack of G6 binding to hv1263 encoding IGHHV1-69 Abs, modeling of L54 in the hG6.3/D80 complex structure suggests substantial losses in vdW contact likely destabilizes the intermolecular interface with hG6.3 (Figure 6). Thus, the highly specific yet broad range of binding activities of G6 represents a unique property that has not been described for other anti-id* Abs.

We further defined the structural features of the 51p1 alleles that would lead to a loss of the G6 idiotope but retention of HA binding and vice versa. The HV1-69-sBnAb family is defined, at least in part, by critical amino acid substitutions in the VH segment including germline CDR-H2 (Ile52AspGlu54GTA) at positions I52 or P52a together with triad of a hydrophobic amino acid at position 53, Phe54, and properly positioned CDR-H3 Tyr (Avnir et al., 2014). The majority of tested HV1-69-sBnAbs did not bind to G6 despite the fact that all were comprised of the IGHHV1-69 51p1 group (Figure 1A) and encode CDR-H2 F54 (Potter et al., 1999). The three G6-reactive HV1-69 sBnAbs had the common features of P52a/G substitutions, I53V/M and hydrophobic substitutions, and a triplet of CDR-H3 Tyrs (Avnir et al., 2014). The triple tyrosine motif in D80 is involved in an extensive pi-stacking interaction network that may pre-organize the binding epitope and promote tight binding to G6 and HA (Figure 5); related tyrosine pi-stacking interactions may also be involved in 70-1F02 and CR6331 binding to both G6 and HA. Interestingly, the chimeric VH1-69/F10 CDR-H2 I52S and I53M variants bind with decreased affinity with respect to G6 compared to VH1-69/F10 (Figure 2B), while the VH1-69/F10 CDR-H2 I52S variant is capable of binding to HA, but VH1-69/F10 and VH1-69/F10 CDR-H2 I53M do not (Avnir et al., 2014). The flexible CDR-H2 residues introduced by the P52a/G substitutions together with germline A57 may increase CDR-H2 loop flexibility and are features of the G6 id* HV1-69-sBnAbs whereas many of the G6 non-reactive HV1-69-sBnAbs contain proline at these positions. G6 binding can be lost in multiple ways, including due to a substitution of the critical germline N58 itself, or a proline substitution at the preceding A57 that causes N58 to lose intermolecular interactions. These results suggest HV1-69-sBnAbs are highly sensitive to structural variation around the core F54 contact residue that appear to greatly affect the conformation of the CDR-H2 loop with respect to optimal binding for HA and G6 idiotope expression.

In conclusion, the growing recognition that IGHV polymorphism and biased VH germline gene usage are important, albeit underestimated, features of the Ab response in health and disease is reshaping our thinking on how this knowledge can be applied to precision medicine. In the area of host defense, hG6.3 could be used to monitor the loss of G6 CRI in the circulating IGHHV1-69 Ab pool as B cells evolve to become memory B cells and HV1-69-sBnAbs secreting plasma cells in response to seasonal (Corti et al., 2010) and emerging HA-stem derived “universal” influenza vaccines (Krammer, 2015). The G6 CRI may also be useful for monitoring B cells and Abs that bind to and neutralize HCV and MERS-CoV, respectively (Chan et al., 2001; Tang et al., 2014; Ying et al., 2015). In the emerging field of oncoimmunology, the high presence of G6 CRI on unmaturated BCRs seen in IGHHV1-69-encoded B-CLL (Chang et al., 2016; Hamblin et al., 1999), and the recognition of other IGHHV1-69 CRI orders involving pathophysiological B cell expansions (Chan et al., 2001; Miklos et al., 2000) could provide an avenue of therapeutic intervention through hG6.3-mediated immune clearance. In addition, hG6.3-based idiotype mapping (Idio-Seq) could add an important new dimension to the field of immune recognition where advances in the high-throughput sequencing and analysis of expressed Ab repertoires (BCR-seq) in peripheral blood B cells and LC-MS/MS proteomic spectrototyping of antigen-specific Abs (IG-seq) allow us to characterize, with unparalleled accuracy, the serological repertoire to each of the Ab components (Lee et al., 2016). This knowledge will aid in our understanding of how the serological repertoire changes in response to vaccination, infection, cancer, and autoimmune diseases. Defining the expressed G6 CRI repertoire and understanding how Abs encoding a IGHHV1-69 VH segment germline configuration participate in wellness and pathologic humoral responses (Watson et al., 2017) could be important part of this ongoing paradigm shift.

**EXPERIMENTAL PROCEDURES**

**Sequence Analysis of Abs**

Abs were numbered according to the Kabat numbering scheme. CDR-H1, H2 are defined according to IMGT’s definitions. For CDR-H3, residues are shown from Cys92 to Trp103 and for CDR-H3/J residues are shown from Cys92 to Ser113. CDR-H4 was defined based on our previous study (Avnir et al., 2014). Ab sequences were analyzed by using either IgBlast (Ye et al., 2013) or IMGT/HighV-QUEST (Alamyar et al., 2012).

**Construction and Expression of HV1-69-sBnAbs Variants**

The HV1-69-sBnAbs variants were constructed and expressed as scFv as described in Avnir et al. (2014). The original (WT) CDR-H3s and light chains were maintained in all analyzed HV1-69-sBnAbs variants.

**Binding Assays of HV1-69-sBnAbs to G6 and hG6.3**

For Abs F10, A66, G17, D7, D8 and H40, standard ELISA assay was performed by coating MaxiSorp plates with G6, adding HV1-69-sBnAbs in the scFv-Fc format, and detecting bound HV1-69-sBnAbs with anti-human Fc conjugated with HRP. For the IgG Abs 1009-3E06, 1009-3B05, 70-5B03, and 70-1F02 (Wrammert et al., 2011) and for scFvs CR6331 and CR6261 (Thrasy et al., 2006) a Biacore T100 instrument was used in which the Abs were flowed over a CMS chip that was immobilized with an anti-mouse-Ab and captured G6. For C9114 scFv-Fc an Octet RED96 instrument was used in which biotinylated-hG6.3 was captured on streptavidin sensor after which the sensor was moved to a well containing the scFv-Fc CR9114 Ab.

**Binding Kinetics Assay of HV1-69-sBnAb Germline Variants**

Biacore T100 single cycle kinetics assays were performed for VH1-69/F10, VH1-69/A66, and VH1-69/CR6261 scFvs by using a CMS chip that was immobilized with an anti-mouse-Ab and captured G6 at a level of ~320 response units (RU). Similarly, the various VH1-69/F10 variants were
analyzed for G6 binding when each variant was used at a single concentration of 2.85 μg/mL.

**B Cell Receptor Cross Linking Assay**
The heavy chain and light chains of the various VH1-69/F10 variants were cloned into a B cell receptor vector and the B cell cross linking assays with G6 or hG6.3 were executed as described previously (Hoot et al., 2013) and as detailed in the Figure 2 legend.

**Protein Expression, Purification, and Crystallization**
For crystallographic purposes, Fab fragments were expressed in insect cells using a baculovirus expression system. Fab fragments were purified using a polyhistidine tag with nickel-affinity chromatography and subsequent size exclusion chromatography. For unbound D80 crystallization, the D80 Fab fragment crystals were grown at 20°C by hanging-drop vapor diffusion in a solution using 20% PEG 4000, 0.2 M CaCl₂, and 0.1 M Tris pH 8.4. D80 crystallized in a P 2₁2₁2₁ space group with 2 molecules in the asymmetric unit and unit cell dimensions of a = 89.0, b = 91.6, and c = 106.8 Å. For D80-G6 complex crystallization, the D80-G6 Fab fragment complex crystals were grown at 20°C by hanging-drop vapor diffusion in a solution using 0.1 M NaH₂SO₄ and 12% PEG 3350. The D80-G6 complex was crystallized in a C 2 1 2 1 space group with 1 molecule in the asymmetric unit and unit cell dimensions of a = 143.2, b = 50.8, and c = 139.7 Å.

**Diffraction Data Collection and Structure Solution**
Diffraction data was collected at cryogenic temperatures using synchrotron radiation at the GM/CA-CAT 23-ID-B beam line at the Argonne National Laboratory (Advanced Photon Source, Chicago, IL). Data was indexed and scaled using xia2 and HKL3000 (Collaborative Computational Project, Number 4, 1994; Kabach, 2010; Minor et al., 2006; Winter et al., 2012). Molecular replacement solutions were determined using M-RAGE in PHENIX (Adams et al., 2010; Bunkóczi et al., 2013). Cycles of rigid body, restrained, and TLS refinement with subsequent model building were performed using phenix.refine in PHENIX and Coot, respectively (Adams et al., 2010; Emsley et al., 2010).

**Binding Assays of the D80 F54L Variant**
Mutagenesis of D80 F54 scFv-Fc to D80 L54 scFv-Fc was achieved using QuikChange Lightning kit according to manufacturer’s protocol. Binding assays were performed using the Octet RED96 instrument with streptavidin QuikChange Lightning kit according to manufacturer’s protocol. Binding Assays of the D80 F54L Variant was achieved using the ELISA assay and humanization of hG6.3 V.B.K. performed the humanization of hG6.3 and the biological studies. M.G. and R.J. performed the humanization of hG6.3. A.T.M. and L.S. performed the BCR studies. T.F.K. and J.D.J. designed the research and obtained funding. J.P.W. and R.W.F designed the research, obtained funding, and edited the manuscript. Q.Z. co-supervised the humanization, mutagenesis, and phage display studies. N.K.Y. co-supervised crystallographic, structural analysis, and molecular modeling studies, designed the research, and wrote and edited the manuscript. C.A.S. co-supervised crystallographic, structural analysis, and molecular modeling studies, wrote the manuscript, designed the research, and obtained funding. W.A.M. conceived the project, co-supervised humanization, mutagenesis, phage display, and molecular modeling studies, wrote and edited the manuscript, designed the research, and obtained funding.

**DECLARATION OF INTERESTS**
W.A.M. has a financial interest in AR Pharma, the licensee of hG6.3. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or Department of Defense.

Received: August 25, 2017
Revised: November 4, 2017
Accepted: November 15, 2017
Published: December 12, 2017

**REFERENCES**


